The Small Molecule Penalty Mindlessly Pulls the Brake on Medical Innovation
September 13, 2023 (Alexandria, Virginia) — Today Consumer Action for a Strong Economy (CASE), urged the House Committee on...
CASE Op-Ed in Townhall.Com: House Committee Must Safeguard American Healthcare Innovation From China
April 26, 2023 If somebody stole your car, hacked your bank account, and emptied your retirement savings, your response...
CASE Op-Ed in The Daily Caller: Congress And Biden’s Regulations Made Healthcare More Expensive In 2022 — The GOP Must Fix That In 2023
January 25, 2023 Make no mistake, Congress and the Biden administration took a sledgehammer to the American healthcare system...
Next on the WTO’s Agenda: Attacking Medical Innovation, Again
October 10, 2022 With the backing of President Biden, the World Trade Organization (WTO) has taken steps to tear down...
CASE Statement Opposing Biden Agreement Undermining Vaccine IP Rights Critical to Patients
March 24, 2022 Today, Chairman of Consumer Action for a Strong Economy, Gerard Scimeca, issued the following statement condemning the...
CASE Statement: Pending Congressional Amendment to Have Devastating Effect on Medical Innovation
March 10, 2020 Contact: Gerard Scimeca, CASE co-founder and Chairman CASE Statement in Opposition to “No Ban Act” Adoption of...
CASE TV Campaign Urges President Trump NOT to Let Speaker Pelosi Give Handout to Canada in Trade Deal
December 23, 2019 In what could have been the policy hallmark of his first term in office, President Trump originally...
.@POTUS’ IRA is driving up Part D premiums for millions of Medicare beneficiaries, yet Dems like @SenSanders continue to help tout this disastrous legislation. The Biden-Harris @WhiteHouse is misleading the public on their policy’s real impact.
Two weeks from election day, the supposedly independent @FCC is proposing price regulation of #broadband by restricting what data plans companies can offer.
By prohibiting usage-based plans, the FCC would end up increasing prices FOR EVERYONE, including low-data users!
CASE Letter Urges FDA & FTC to Scrutinize Deal Between L’Oréal and Galderma -- "Both companies are currently under investigation or facing sizable lawsuits from claims that they have used harmful chemicals in their products."
https://caseforconsumers.org/2024/10/21/case-letter-urges-fda-ftc-to-scrutinize-deal-between-loreal-and-galderma/